drugset
drugset / Trial / NCT04451434

Study of Danicopan in Participants of Japanese Descent

NCT04451434 ↗

Phase 1 Completed 9 enrolled Alexion Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of danicopan after a single-dose oral administration under fed and fasting conditions to participants of Japanese descent.

Timeline

Start
2020-08-17
Primary completion
2020-09-28
Completion
2020-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicopan Small molecule 200 mg Oral
Subject Danicopan Small molecule 400 mg Oral

Indications

No indication recorded.